A study from the Buck Institute for Research on Aging reports that the APOE2 variant—long associated with lower Alzheimer’s risk and exceptional longevity—helps human neurons better withstand DNA damage and resist a senescent, dysfunctional state. The work, published in the journal Aging Cell, used engineered human stem-cell–derived neurons and mouse models to explore how common APOE gene forms may influence cellular stress responses.
The research, published in Aging Cell, examined how different versions of the apolipoprotein E (APOE) gene shape neuronal responses to damage. Prior population and genetic research has linked APOE2 with reduced risk of Alzheimer’s disease and longer life, while APOE4 is widely recognized as the strongest common genetic risk factor for late-onset Alzheimer’s disease.
In cell-based experiments, the team used human induced pluripotent stem cells (iPSCs) engineered so they differed at the APOE locus while remaining otherwise genetically matched. The researchers generated multiple neuronal types, including inhibitory (GABAergic) neurons and a separate model of induced excitatory (glutamatergic) neurons, then subjected the cells to stressors that trigger DNA damage. Across these models, neurons carrying APOE2 showed lower signs of DNA damage and were less prone to enter cellular senescence than isogenic APOE3 or APOE4 neurons.
Single-cell analyses reported in the paper also indicated that APOE2 inhibitory neurons were enriched for DNA repair and related signaling pathways, while APOE4 neurons showed gene-expression signatures linked to Alzheimer’s disease biology.
The study also extended its findings to animal work. In mice carrying human APOE variants, the researchers reported differences consistent with APOE2 being associated with more resilient nuclear and DNA-damage–related features in hippocampal tissue compared with APOE3 or APOE4.
Senior author Lisa M. Ellerby said the results point toward therapeutic strategies that aim to enhance DNA repair mechanisms or reduce the burden of senescent cells in the brain—approaches the authors suggest could potentially mimic some of APOE2’s protective effects. The researchers also reported that adding recombinant APOE2 protein to APOE4 neurons reduced molecular signals associated with damage, an early finding they say warrants further study to determine whether such effects could be translated into safe, effective treatments.
The authors emphasized that the work focuses on cellular and preclinical models and does not by itself demonstrate a treatment for Alzheimer’s disease, though it offers a mechanistic framework for exploring how genetic risk and protection might operate at the level of neuronal aging.
